Montrusco Bolton Investments Inc. Has $186.71 Million Stock Position in IDEXX Laboratories, Inc. $IDXX

Montrusco Bolton Investments Inc. boosted its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 93.4% in the 1st quarter, HoldingsChannel reports. The firm owned 342,120 shares of the company’s stock after buying an additional 165,188 shares during the period. IDEXX Laboratories accounts for about 2.8% of Montrusco Bolton Investments Inc.’s investment portfolio, making the stock its 14th largest holding. Montrusco Bolton Investments Inc.’s holdings in IDEXX Laboratories were worth $186,707,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. SHP Wealth Management bought a new stake in IDEXX Laboratories during the fourth quarter worth about $26,000. Virtus Advisers LLC bought a new position in shares of IDEXX Laboratories in the third quarter valued at approximately $26,000. Park Place Capital Corp acquired a new position in shares of IDEXX Laboratories in the 4th quarter worth approximately $29,000. Mowery & Schoenfeld Wealth Management LLC boosted its holdings in shares of IDEXX Laboratories by 58.8% in the 4th quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company’s stock worth $37,000 after acquiring an additional 20 shares in the last quarter. Finally, Wormser Freres Gestion boosted its holdings in shares of IDEXX Laboratories by 671.4% in the 4th quarter. Wormser Freres Gestion now owns 54 shares of the company’s stock worth $37,000 after acquiring an additional 47 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

IDXX has been the subject of a number of recent analyst reports. Citigroup began coverage on IDEXX Laboratories in a report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price target for the company. Weiss Ratings raised IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, June 25th. UBS Group decreased their target price on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a report on Tuesday, April 28th. Stifel Nicolaus lowered their target price on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research note on Tuesday, March 31st. Finally, Wall Street Zen raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Saturday, June 13th. Seven analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $751.00.

IDEXX Laboratories Price Performance

NASDAQ:IDXX opened at $557.80 on Friday. The company has a market cap of $44.00 billion, a price-to-earnings ratio of 41.08, a P/E/G ratio of 3.05 and a beta of 1.55. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.12. The stock’s fifty day moving average price is $555.31 and its two-hundred day moving average price is $609.16. IDEXX Laboratories, Inc. has a 52-week low of $506.91 and a 52-week high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The company had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.12 billion. During the same quarter in the previous year, the company posted $2.91 earnings per share. The firm’s quarterly revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, analysts anticipate that IDEXX Laboratories, Inc. will post 14.68 EPS for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.